2022
An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
TORRENTE, María, Pedro A SOUSA, Roberto HERNÁNDEZ, Mariola BLANCO, Virginia Calvo Ana COLLAZO et. al.Základní údaje
Originální název
An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
Autoři
TORRENTE, María, Pedro A SOUSA, Roberto HERNÁNDEZ, Mariola BLANCO, Virginia Calvo Ana COLLAZO, Gracinda R GUERREIRO, Beatriz NÚÑEZ, Joao PIMENTAO, Juan Cristóbal SÁNCHEZ, Manuel CAMPOS, Luca COSTABELLO, Vít NOVÁČEK (203 Česká republika, garant, domácí), Ernestina MENASALVAS, María Esther VIDAL, Mariano PROVENCIO a Virginia CALVO
Vydání
CANCERS, SWITZERLAND, MDPI, 2022, 2072-6694
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10201 Computer sciences, information science, bioinformatics
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.200
Kód RIV
RIV/00216224:14330/22:00127570
Organizační jednotka
Fakulta informatiky
UT WoS
000846265900001
Klíčová slova česky
artificial intelligence; data integration; cancer patients; patient stratification; precision oncology; decision support system
Klíčová slova anglicky
artificial intelligence; data integration; cancer patients; patient stratification; precision oncology; decision support system
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 6. 4. 2023 13:36, RNDr. Pavel Šmerk, Ph.D.
Anotace
V originále
Background: Artificial intelligence (AI) has contributed substantially in recent years to the resolution of different biomedical problems, including cancer. However, AI tools with significant and widespread impact in oncology remain scarce. The goal of this study is to present an AI-based solution tool for cancer patients data analysis that assists clinicians in identifying the clinical factors associated with poor prognosis, relapse and survival, and to develop a prognostic model that stratifies patients by risk. Materials and Methods: We used clinical data from 5275 patients diagnosed with non-small cell lung cancer, breast cancer, and non-Hodgkin lymphoma at Hospital Universitario Puerta de Hierro-Majadahonda. Accessible clinical parameters measured with a wearable device and quality of life questionnaires data were also collected. Results: Using an AI-tool, data from 5275 cancer patients were analyzed, integrating clinical data, questionnaires data, and data collected from wearable devices. Descriptive analyses were performed in order to explore the patients’ characteristics, survival probabilities were calculated, and a prognostic model identified low and high-risk profile patients. Conclusion: Overall, the reconstruction of the population’s risk profile for the cancer-specific predictive model was achieved and proved useful in clinical practice using artificial intelligence. It has potential application in clinical settings to improve risk stratification, early detection, and surveillance management of cancer patients.